Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
Immunome, Inc. (IMNM)
Company Research
Source: Yahoo! Finance
best-in-class targeted cancer therapies, today announced that Immunome management will present at Guggenheim's Emerging Outlook: Biotech Summit on February 11, 2026, at 9 a.m. ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com . The webcast replay will be available after the conclusion of the live presentation for approximately 30 days. About Immunome, Inc. Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recentl
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome: Upcoming NDA, Valuation, And Investment Case [Seeking Alpha]Seeking Alpha
- Immunome (IMNM) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMNM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "selMarketBeat
- Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative? [Yahoo! Finance]Yahoo! Finance
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Immunome (IMNM) had its price target raised by Craig Hallum from $33.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/23/26 - Form 4
- 3/20/26 - Form 144
- IMNM's page on the SEC website